In an elderly patient with rib fractures after a ground‑level fall and a significant cardiac history who is taking apixaban (Eliquis) at home, when should apixaban be resumed?

Resumption of Apixaban After Rib Fractures in an Elderly Anticoagulated Patient

Resume apixaban 48–72 hours (2–3 days) after the rib fracture injury once adequate hemostasis is confirmed and there is no evidence of ongoing bleeding. 1

Key Decision Points for Timing

Assess Bleeding Risk and Hemostasis

• Confirm hemostasis is adequate before restarting anticoagulation. This means stable hemoglobin levels, no expanding hematomas, and controlled pain without signs of active bleeding. 1
• Rib fractures themselves do not typically require surgical intervention, so the resumption timeline follows trauma rather than post-surgical protocols. 2
• Elderly patients on anticoagulation with rib fractures have longer hospital stays but no increased mortality or major morbidity compared to non-anticoagulated patients. 2

Standard Resumption Protocol for Apixaban

For most patients with rib fractures and stable hemostasis:

• Resume full-dose apixaban (5 mg twice daily or the patient's home dose) at 48–72 hours post-injury. 1
• The FDA label states that apixaban should be restarted "as soon as adequate hemostasis has been established" after procedures or trauma. 3

For patients at particularly high thrombotic risk (e.g., mechanical valve, recent stroke, CHA₂DS₂-VASc ≥4):

• Consider initiating a reduced dose of 2.5 mg twice daily for the first 2–3 days, then escalating to full therapeutic dose (5 mg twice daily). This approach balances early thrombotic protection against rebleeding risk. 1
• Alternatively, parenteral anticoagulation with unfractionated heparin can be started within 1–3 days with close monitoring, given its short half-life and reversibility with protamine. 4

No Bridging Required

• Do not use heparin bridging during the 24–72 hour interruption period. Apixaban's rapid onset (peak levels at 1–3 hours) and offset (half-life 7–8 hours) make bridging unnecessary and potentially harmful. 5, 1
• Bridging anticoagulation is not generally required during the brief interruption after trauma or procedures. 3

Special Considerations in This Elderly Patient

Renal Function Assessment

• Check creatinine clearance (CrCl) using the Cockcroft-Gault formula before resuming apixaban. 6
• If CrCl 30–50 mL/min, apixaban clearance is modestly reduced but dose adjustment for resumption is typically not required unless the patient already meets dose-reduction criteria (age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL—two of three criteria). 3
• Apixaban has only 25% renal clearance, making it safer than dabigatran (80% renal) in elderly patients with renal impairment. 1

Age-Related Pharmacokinetics

• Elderly patients (especially those ≥80 years) may have prolonged apixaban half-lives and detectable drug levels for >10 days after the last dose. 7
• In high-risk elderly patients with multiple comorbidities, consider measuring apixaban anti-Xa levels before resumption if there is concern about residual drug effect or if the patient has severe renal impairment. 7, 8

Cardiac History and Thrombotic Risk

• Patients with significant cardiac history (atrial fibrillation, prior stroke/TIA, heart failure) are at high thrombotic risk and benefit from earlier anticoagulation resumption. 4
• Delaying anticoagulation beyond 72 hours in high-risk patients increases the risk of stroke or systemic embolism without meaningfully reducing bleeding risk once hemostasis is established. 4

Common Pitfalls to Avoid

Do Not Delay Indefinitely Due to Fear of Bleeding

• Rib fractures in anticoagulated patients do not increase mortality or major bleeding complications compared to non-anticoagulated patients. 2
• Preinjury anticoagulation with factor Xa inhibitors (apixaban, rivaroxaban) does not increase perioperative blood loss or transfusion rates in trauma patients, even with expedited surgery within 24 hours. 9

Do Not Resume Too Early

• Avoid resuming full-dose apixaban within 24 hours post-trauma, as this markedly increases major bleeding risk comparable to therapeutic-dose low-molecular-weight heparin. 5, 1

Do Not Apply Dabigatran Protocols to Apixaban

• Dabigatran requires longer interruption (4–5 days) due to 80% renal excretion; apixaban's 25% renal clearance allows shorter interruption and resumption windows. 10, 1

Do Not Ignore Dose-Reduction Criteria

• If the patient meets two of three criteria (age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL), the home dose should be 2.5 mg twice daily, not 5 mg twice daily. 3
• Underdosing apixaban (giving 2.5 mg twice daily when 5 mg twice daily is indicated) is the most common prescribing error and occurs in 9.4–40.4% of apixaban prescriptions. 11

Practical Algorithm

1. At 48 hours post-injury:

   • Assess hemoglobin stability (no drop >2 g/dL in 24 hours)
   • Confirm no expanding hematomas or hemothorax
   • Check pain control and respiratory function

2. If hemostasis is adequate:

   • Resume apixaban at home dose (5 mg or 2.5 mg twice daily based on dose-reduction criteria) 3
   • If very high thrombotic risk, consider starting 2.5 mg twice daily for 2 days, then escalating 1

3. If hemostasis is uncertain or high rebleeding risk:

   • Delay to 72 hours and reassess
   • Consider unfractionated heparin infusion if thrombotic risk is unacceptably high 4

4. Monitor closely for 48 hours after resumption:

   • Daily hemoglobin
   • Clinical signs of bleeding or thrombosis